The purpose of this study is to collect blood and tumor tissue samples (when possible) from kidney cancer patients for various indicators of how their cancer is behaving in response to treatment. These indicators are referred to as biomarkers. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease. Biomarkers that will be studied include circulating tumor cells, circulating tumor DNA, and large oncosomes. Circulating tumor cells are rare cells in the bloodstream that have broken off from a tumor and could possibly lead to future metastases (spreading of cancer). The results of this pilot study will help determine whether it will be possible to conduct future studies that evaluate the use of blood biomarkers as a guide to clinical decision-making or monitoring treatment response for kidney cancer.